Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial)

Clinical Breast Cancer

Volumn 8, Issue 2, 2008, Pages 192-194

  Guarneri, Valentina ^a   Frassoldati, Antonio ^a   Piacentini, Federico ^a   Jovic, Gordana ^a   Giovannelli, Simona ^a   Oliva, Cristina ^b   Conte, PierFranco ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Epidermal growth factor receptor; Immunohistochemistry; Pathologic complete response

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; KI 67 ANTIGEN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN KINASE B; TAXANE DERIVATIVE; TRASTUZUMAB;

APOPTOSIS; BREAST CANCER; CANCER INVASION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; TREATMENT OUTCOME;

EID: 43249090582     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.022     Document Type: Article

References (14)

1. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Presented at: the 28th Annual San Antonio Breast Cancer Symposium; December 8-11, 2005; San Antonio, TX. Abstract 1.
2. EH Romond EA Perez J Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
3. MJ Piccart-Gebhart M Procter B Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
4. H Joensuu PL Kellokumpu-Lehtinen P Bono Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 2006 809 820
5. AU Buzdar NK Ibrahim D Francis Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2–positive operable breast cancer J Clin Oncol 23 2005 3676 3685
6. N Wolmark J Wang E Mamounas Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 30 2001 96 102
7. V Guarneri K Broglio SW Kau Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 2006 1037 1044
8. R Nahata F Esteva Molecular mechanism of trastuzumab resistance Breast Cancer Res 8 2006 215
9. GE Konecny MD Pegram N Venkatesan Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer Res 66 2006 1630 1639
10. NL Spector W Xia H Burris III Study of the biological effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies J Clin Oncol 23 2005 2502 2512
11. Finn RS, Press MF, Dering J, et al. Biomarker analysis of lapatinib with paclitaxel versus paclitaxel as first-line treatment in 579 patients with metastatic breast cancer. Presented at: the 14th European Cancer Conference; September 23-27, 2007; Barcelona, Spain. Abstract 2097.
12. W Xia LH Liu P Ho Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016 Oncogene 23 2004 646 653
13. CE Geyer J Forster D Lindquist Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2006 2733 2743
14. AM Storniolo H Burris M Pegram A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen J Clin Oncol 23 16 suppl 2005 18s (Abstract 559).